Alternative Solid Forms: Co-crystals

Johan Wouters, Dario Braga, Fabrizia Grepioni, Luc Aerts, Luc Quéré

Research output: Contribution in Book/Catalog/Report/Conference proceedingChapter

Abstract

The relevance of co‐crystals for pharmaceutical development is demonstrated by the constant growth of the number of papers and patents published in the two last decades. Co‐crystallization appears to be an efficient means to modulate the solid state properties of a pharmaceutical active ingredient (API) within the crystalline state. It is also a crystal engineering approach enabling to prepare original materials, including co‐drugs. Co‐crystallization is therefore a route to innovation and opens perspectives to patent protection. Alternatively, co‐crystal formation may represent an undesired or unexpected outcome of molecular complexation, for example in the drug product. This observation underlines the importance of a detailed study on the solid state chemistry not only of the pure API, but also of its combinations with the individual components in the formulation.
Original languageEnglish
Title of host publicationPolymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development
EditorsRolf Hilfiker, Markus von Raumer
PublisherWiley
Chapter3
Number of pages32
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Alternative Solid Forms: Co-crystals'. Together they form a unique fingerprint.

  • Equipment

  • Cite this

    Wouters, J., Braga, D., Grepioni, F., Aerts, L., & Quéré, L. (2018). Alternative Solid Forms: Co-crystals. In R. Hilfiker, & M. von Raumer (Eds.), Polymorphism in the Pharmaceutical Industry : Solid Forms and Drug Development Wiley. https://doi.org/10.1002/9783527697847.ch3